Collplant Biotechnologies Ltd logo

Collplant Biotechnologies Ltd(CLGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 10 days
PROFIT SINCE LAST BUY
-10.54% ▼
LAST CLOSE
$3.65
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CLGN

11/13/2026: CLGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

CollPlant Biotechnologies Ltd is a clinical-stage regenerative medicine company specializing in plant-derived recombinant human collagen (rhCollagen) for medical aesthetics and 3D bioprinting. The company's primary operational strengths lie in its unique xeno-free material platform and a major global licensing agreement with AbbVie for dermal fillers. Its core growth opportunity stems from expanding its bioink product sales and advancing innovative pipeline products like regenerative breast implants. However, the company faces notable execution, funding, and regulatory risks typical of early-stage biotechnology firms, alongside competition from established medical device giants. CollPlant suits high-risk growth investors who can tolerate volatility while monitoring clinical progress and milestone inflows.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high long-term growth potential from breakthrough regenerative platforms, balanced by early-stage commercial scale.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp price movements driven by clinical updates, regulatory milestones, or partnership news.
Value investorWeak fitThe company is currently unprofitable and invests heavily in clinical research rather than producing steady earnings.
Dividend investorWeak fitCollPlant does not pay dividends and retains all capital to support ongoing biotechnology development.
Low-risk investorWeak fitSmall-cap clinical-stage biotechnology equities carry high price volatility and execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow market capitalization and clinical-stage status make the stock sensitive to news flow and market sentiment.
Valuation riskMedium / highValuation relies heavily on future discounted cash flows from pipeline assets rather than current earnings.
Competition risk (biomaterial and medtech competition)HighWell-funded medtech competitors can challenge adoption if alternative technologies gain faster market acceptance.
Business qualityMediumProprietary technology is robust, but commercialization maturity is still developing.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighClinical trial outcomes, regulatory approvals, and partner collaboration execution dictate long-term success.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.27M USD
Price to earnings Ratio -
1Y Target Price 11.12
Price to earnings Ratio -
1Y Target Price 11.12
Volume (30-day avg) 60.8K shares
Beta 0.57
52 Weeks Range 2.64 - 22.50
Updated Date 11/15/2026
52 Weeks Range 2.64 - 22.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -9.33

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -80.2%
Avg. Invested days 13
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CLGN receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
CLGN has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+30.8%) and strong revenue growth (+360.4%) are partially offset by weak cash generation (FCF margin -398.4%), weak profitability (net margin -484.6%).

Financial Health Rating

★★★★★
CLGN's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 37.8%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CLGN's strongest growth driver at +360.4% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+30.8%, solid) and free-cash-flow growth (+35.2%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 7.4% (soft) and 28.1% of outstanding shares are publicly tradable (soft). Insider ownership of 20.85% supports management-shareholder alignment.

Top 5 Institutional Investors

Parallel Advisors, LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
CLGN generates approximately $263 of gross profit, $-4,843 of operating income, and $-3,984 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CLGN has a relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Milestone LicensingUpfront license fees and development milestone payments from global partners such as AbbVie.Lumpy revenue streams that spike when major clinical or regulatory milestones are achieved.
Bioinks and BiomaterialsCommercial sales of Collink.3D bioinks and rhCollagen raw materials to research institutions and commercial partners.Provides steady, early-stage product revenue from the scientific research and 3D bioprinting community.
Tissue Repair ProductsSales of VergenixSTR for tendinopathy and wound care products primarily marketed in Europe.Direct commercial product sales contributing modest recurring international revenue.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 80
Enterprise Value 11.33M
Price to Sales(TTM) 44.88
Enterprise Value 11.33M
Price to Sales(TTM) 44.88
Enterprise Value to Revenue 35.62
Enterprise Value to EBITDA -5.97
Shares Outstanding 3.08M
Shares Floating 864.52K
Shares Outstanding 3.08M
Shares Floating 864.52K
Percent Insiders 20.85
Percent Institutions 7.36

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.